# What Is Meningitis B and Why Vaccine Access Remains Limited for Teenagers

Meningitis B, caused by the bacterium Neisseria meningitidis serogroup B, ranks among the most serious infections teenagers face. The disease can cause meningitis, septicemia, and death within hours of symptom onset. Survivors often experience permanent neurological damage, hearing loss, or limb amputation.

The Bexsero vaccine protects against this serogroup, yet access remains restricted in many countries including the UK. Health authorities do not offer universal vaccination to all teenagers, only to select groups deemed highest risk.

The primary reason centers on cost-effectiveness. Meningitis B remains rare in most developed nations. Vaccinating entire age groups would require enormous public health spending to prevent a relatively small number of cases. Health agencies conduct rigorous cost-benefit analyses, and universal vaccination has not met their thresholds for routine population programs.

Certain groups receive targeted protection. These include teenagers with specific immune system disorders, asplenic individuals (those without spleens), and close contacts of confirmed meningitis B cases. University students in some regions also gain access, as crowded dormitory settings increase transmission risk.

The vaccine's effectiveness also matters. Bexsero provides strong protection, but immunity wanes over time. This reality influences how health systems prioritize limited vaccination resources.

Ongoing debate challenges these policies. Some medical experts and parent advocacy groups argue that the vaccine's safety profile justifies broader use, particularly given meningitis B's severity and rapid progression. They contend that even rare disease cases inflict devastating harm on families and communities.

Health authorities regularly review meningitis B epidemiology and vaccination data. As vaccine costs decline and supply increases, policies may shift toward broader access. Parents of teenagers should discuss their individual risk factors with healthcare providers